Holen Sie sich die Stockscreener-App
2.99
2.29%
-0.07
Handel nachbörslich:
2.97
-0.02
-0.67%
Schlusskurs vom Vortag:
$3.06
Offen:
$3.01
24-Stunden-Volumen:
371.04K
Relative Volume:
0.09
Marktkapitalisierung:
$67.12M
Einnahmen:
$32.77M
Nettoeinkommen (Verlust:
$-101.98M
KGV:
-0.3111
EPS:
-9.6101
Netto-Cashflow:
$-112.43M
1W Leistung:
-13.08%
1M Leistung:
-8.28%
6M Leistung:
-51.33%
1J Leistung:
-82.14%
1-Tages-Spanne:
$2.91
$3.03
1-Wochen-Bereich:
$2.91
$3.57
52-Wochen-Spanne:
$1.35
$26.83
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Firmenname
X 4 Pharmaceuticals Inc
Sektor
Branche
Telefon
857-529-8300
Adresse
61 NORTH BEACON STREET, BOSTON, MA
Vergleichen Sie XFOR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
2.99 | 68.69M | 32.77M | -101.98M | -112.43M | -9.6101 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-12-12 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2023-08-30 | Fortgesetzt | B. Riley Securities | Buy |
| 2022-12-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-12 | Eingeleitet | Piper Sandler | Overweight |
| 2019-12-23 | Eingeleitet | Oppenheimer | Outperform |
| 2019-12-18 | Eingeleitet | ROTH Capital | Buy |
| 2019-12-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-12-05 | Eingeleitet | B. Riley FBR | Buy |
| 2019-06-07 | Eingeleitet | Stifel | Buy |
| 2019-06-05 | Eingeleitet | Cowen | Outperform |
Alle ansehen
X 4 Pharmaceuticals Inc Aktie (XFOR) Neueste Nachrichten
Will X4 Pharmaceuticals Inc. stock benefit from AI adoptionTreasury Yields & Fast Gaining Stock Reports - newser.com
Will X4 Pharmaceuticals Inc. stock benefit from commodity pricesPortfolio Update Summary & Stepwise Swing Trade Plans - newser.com
Using data filters to optimize entry into X4 Pharmaceuticals Inc.2025 Price Action Summary & Risk Adjusted Buy/Sell Alerts - newser.com
Will X4 Pharmaceuticals Inc. stock benefit from upcoming earnings reportsJuly 2025 Technicals & Smart Allocation Stock Tips - newser.com
Will X4 Pharmaceuticals Inc. (48Q0) stock outperform foreign stocksWeekly Risk Summary & Scalable Portfolio Growth Methods - newser.com
Combining machine learning predictions for X4 Pharmaceuticals Inc.July 2025 Price Swings & Reliable Breakout Stock Forecasts - newser.com
Advanced analytics toolkit walkthrough for X4 Pharmaceuticals Inc.July 2025 Action & Community Consensus Picks - newser.com
Layoff Tracker: Ferring To Cut 500 Employees as Part of Business Model Shift - BioSpace
Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - FinancialContent
Will X4 Pharmaceuticals Inc. stock benefit from green energy trendsJuly 2025 Update & Verified Momentum Watchlists - newser.com
Ranking X4 Pharmaceuticals Inc. among high performing stocks via tools2025 Market Trends & Verified Entry Point Signals - newser.com
Is it time to cut losses on X4 Pharmaceuticals Inc.Weekly Stock Recap & Verified Entry Point Signals - newser.com
Does X4 Pharmaceuticals Inc. show high probability of reboundMarket Activity Report & Reliable Volume Spike Alerts - newser.com
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by QRG Capital Management Inc. - MarketBeat
How X4 Pharmaceuticals Inc. (48Q0) stock trades pre earningsQuarterly Market Review & Fast Gaining Stock Reports - newser.com
What analysts say about X4 Pharmaceuticals Inc stockTrading Volume Trends & Free Tap Rapid Wealth - earlytimes.in
Is a relief rally coming for X4 Pharmaceuticals Inc. holdersTrade Volume Report & Real-Time Volume Trigger Notifications - newser.com
Analyzing recovery setups for X4 Pharmaceuticals Inc. investors2025 Analyst Calls & Verified Entry Point Detection - newser.com
What does recent volatility data suggest for X4 Pharmaceuticals Inc.Portfolio Value Summary & Advanced Swing Trade Entry Alerts - newser.com
Analyzing X4 Pharmaceuticals Inc. with multi timeframe chartsQuarterly Trade Summary & Fast Entry High Yield Tips - newser.com
X4 Pharmaceuticals Inc 48Q0 Stock Analysis and ForecastPortfolio Allocation Tips & Market Volatility Strategies - earlytimes.in
Finance Watch: Job Cuts At Takeda, Bolt, Innate, X4 As Strategies Shift - insights.citeline.com
How X4 Pharmaceuticals Inc. (48Q0) stock trades after rate cutsIndex Update & Long-Term Growth Plans - newser.com
Chart based exit strategy for X4 Pharmaceuticals Inc.Market Sentiment Summary & Long-Term Safe Investment Ideas - newser.com
Is X4 Pharmaceuticals Inc a good long term investmentEmerging Market Stocks & Small Budget Wealth Tips - earlytimes.in
Goldman Sachs Group Inc. Decreases Holdings in X4 Pharmaceuticals, Inc. $XFOR - Defense World
Does X4 Pharmaceuticals Inc. (48Q0) stock trade below intrinsic valueJuly 2025 Closing Moves & Fast Gain Stock Trading Tips - newser.com
Detecting support and resistance levels for X4 Pharmaceuticals Inc.Swing Trade & Community Verified Trade Alerts - newser.com
Signal strength of X4 Pharmaceuticals Inc. stock in tech scannersWeekly Stock Report & Free High Return Stock Watch Alerts - newser.com
X4 Pharmaceuticals Inc Stock Analysis and ForecastStock Correlation Metrics & Fast Profit Investment Ideas - earlytimes.in
Finanzdaten der X 4 Pharmaceuticals Inc-Aktie (XFOR)
Umsatz
Nettogewinn
Free Cashflow
ENV
X 4 Pharmaceuticals Inc-Aktie (XFOR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Baldry Mark | Chief Commercial Officer |
Nov 15 '24 |
Buy |
0.34 |
13,404 |
4,598 |
129,173 |
| Ragan Paula | President and CEO |
Jan 24 '25 |
Sale |
0.45 |
76,473 |
34,719 |
1,087,386 |
| Mostafa Adam S. | Chief Financial Officer |
Jan 24 '25 |
Sale |
0.45 |
74,773 |
33,947 |
0 |
| Baldry Mark | Chief Commercial Officer |
Jan 24 '25 |
Sale |
0.45 |
29,159 |
13,241 |
94,123 |
| DiBiase Mary | Chief Operating Officer |
Jan 24 '25 |
Sale |
0.45 |
22,258 |
10,094 |
490,980 |
| Arbet-Engels Christophe | Chief Medical Officer |
Jan 24 '25 |
Sale |
0.45 |
11,624 |
5,284 |
14,207 |
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):